pharma.economictimes.indiatimes

Sun Pharma’s Unloxcyt elevated in US cancer care guidelines

Sun Pharmaceutical's Unloxcyt is recommended in cancer care guidelines as a significant treatment option for locally advanced ...
Pharmabiz

Sun Pharma receives NCCN Category 2A Preferred designation for Unloxcyt in advanced CSCC

Sun Pharma receives NCCN Category 2A Preferred designation for Unloxcyt in advanced CSCC: Our Bureau, Mumbai Wednesday, October 21, 2026, 13:15 Hrs [IST] Sun Pharmaceutical Indust ...
allsci

FDA grants Jemperli accelerated approval for MSI-H/dMMR locally advanced rectal cancer

FDA grants accelerated approval to GSK's Jemperli for stage II/III MSI-H or dMMR locally advanced rectal cancer. Read what this means for patients today.
Indian Pharma Post

Sun Pharma’s UNLOXCYT gets NCCN Category 2A recommendation for locally advanced skin cancer

The updated recommendation adds to the drug’s existing Category 2A designation for metastatic cutaneous squamous cell ...
scanx

Sun Pharma’s UNLOXCYT gets NCCN Category 2A nod for laCSCC

UNLOXCYT receives NCCN Category 2A Preferred Designation for laCSCC patients ineligible for surgery or radiation. The ...
Express Pharma

Sun Pharma’s UNLOXCYT receives NCCN Category 2A recommendation for laCSCC

The recommendation adds to UNLOXCYT’s Category 2A designation for metastatic cutaneous squamous cell carcinoma, assigned in ...
EquityBulls

Sun Pharma Announces NCCN Category 2A Preferred Designation for UNLOXCYT in Locally Advanced CSCC

Sun Pharmaceutical Industries Ltd today announced that its anti-PD-L1 antibody, UNLOXCYT® (cosibelimab-ipdl), has been ...